Menin Inhibitors in AML: Targeting KMT2A-Rearranged and NPM1-Mutated Disease

Introduction

AML is increasingly managed as a collection of genetically defined diseases rather than as a single therapeutic entity. Molecular profiling now informs diagnosis, prognostic classification, measurable residual disease assessment, clinical-trial eligibility, and the use of agent-specific targeted therapies.

This shift has already changed treatment for selected patients with FLT3, IDH1, and IDH2 mutations. The approved setting, treatment partner, and demonstrated benefit differ among individual targeted agents, so these therapies should not be presented as a uniform drug class.

Menin inhibitors extend this precision approach to two clinically important groups:

1. Acute leukemias with KMT2A translocations

2. AML with susceptible NPM1 mutations

Menin inhibitors are an important therapeutic advance, but they are not definitive curative treatments. The currently approved agents can induce remissions in selected patients with relapsed or refractory disease and may create an opportunity for allogeneic hematopoietic stem cell transplantation in some responders. Current evidence does not establish that menin-inhibitor treatment before transplantation improves relapse rates, overall survival, or other post-transplant outcomes.

For clinicians, the practical questions now involve identifying molecularly eligible patients, selecting the appropriate agent, anticipating differentiation syndrome, managing QTc and electrolyte abnormalities, preventing clinically significant interactions, and integrating responses into a broader AML treatment strategy.

The article therefore distinguishes carefully among:

• Mechanistic evidence supporting menin dependence

• Response outcomes from single-arm clinical trials

• FDA-approved indications

• Investigational combinations and maintenance strategies

• Unresolved survival and transplantation questions

Current regulatory approvals and pivotal evidence support disciplined, molecularly selected use rather than broad application across AML.

Why Menin Inhibition Matters

KMT2A-rearranged acute leukemia

KMT2A, formerly called MLL, encodes a histone methyltransferase involved in the regulation of hematopoietic gene expression. Rearrangements involving KMT2A produce fusion proteins that maintain aberrant transcriptional programs, including persistent expression of HOX and MEIS1 genes.

KMT2A-rearranged AML is biologically and prognostically heterogeneous. Under the 2022 European LeukemiaNet classification, t(9;11)/MLLT3::KMT2A is categorized as intermediate risk, while many other recurrent KMT2A rearrangements are categorized as adverse risk. Prognosis also depends on age, fusion partner, coexisting genetic abnormalities, prior treatment, response depth, and disease setting.

KMT2A translocations also occur outside AML. The revumenib labeling population includes KMT2A-translocated AML, acute lymphoblastic leukemia, and mixed-phenotype acute leukemia. This distinction matters because revumenib’s KMT2A indication applies to relapsed or refractory acute leukemia, not only AML.

NPM1-mutated AML

NPM1 mutations are among the most common recurrent alterations in AML. In selected newly diagnosed patients, NPM1-mutated disease may have favorable-risk implications, although risk classification depends on treatment setting and coexisting abnormalities.

The favorable-risk framing is less reassuring after relapse, after prior venetoclax exposure, in the presence of adverse cytogenetic findings, or when persistent molecular disease suggests treatment resistance.

NPM1-mutated AML frequently relies on a related menin-KMT2A transcriptional program despite lacking a KMT2A fusion. This shared dependency provides the biological rationale for menin inhibition in both molecular groups.

The degree of menin dependence and treatment sensitivity is not necessarily uniform across all clones, co-mutation patterns, or disease stages. Primary resistance and acquired resistance demonstrate that molecular eligibility does not guarantee response.

Mechanism of Action

Menin is a scaffold protein encoded by MEN1. In KMT2A-rearranged leukemia, menin binds KMT2A fusion complexes and supports transcriptional programs that maintain leukemic self-renewal and impair differentiation.

NPM1-mutated AML can also depend on menin-KMT2A-associated transcriptional maintenance. Experimental models and early clinical studies show that disrupting this interaction can reduce HOX and MEIS1 expression, promote leukemic-cell differentiation, and produce antileukemic activity in susceptible disease.

The mechanistic language should remain appropriately qualified. Menin inhibition can promote differentiation and suppress leukemogenic transcription, but these effects are not universal. Some patients do not respond, and responding disease can acquire resistance.

Differentiation of leukemic cells also helps explain differentiation syndrome, which is a clinically important toxicity of both approved menin inhibitors.

Early clinical studies established proof of concept that targeting a transcriptional regulatory complex can produce meaningful responses in molecularly selected acute leukemia. They did not establish that normal hematopoietic function is uniformly preserved or that menin inhibition lacks substantial hematologic and infectious toxicity.

Current FDA-Approved Menin Inhibitors

Agent	Current labeled population	Important distinction
Revumenib	Adults and pediatric patients aged 1 year or older with relapsed or refractory acute leukemia with a KMT2A translocation	KMT2A status must be determined with an FDA-authorized test
Revumenib	Adults and pediatric patients aged 1 year or older with relapsed or refractory AML with a susceptible NPM1 mutation and no satisfactory alternatives	No FDA-approved NPM1 companion diagnostic is currently available
Ziftomenib	Adults with relapsed or refractory AML with a susceptible NPM1 mutation and no satisfactory alternatives	Not approved for pediatric patients or KMT2A-rearranged AML
Other menin inhibitors	Investigational	Use should generally be limited to clinical trials

The labeled populations are agent-specific. It is inaccurate to describe every menin inhibitor as approved for both KMT2A-rearranged and NPM1-mutated disease.

Evidence for Revumenib

Revumenib is an oral menin inhibitor administered twice daily. Its recommended dosage varies according to patient weight and concomitant use of strong CYP3A4 inhibitors.

KMT2A-translocated acute leukemia

The initial FDA approval was based on a single-arm cohort of the open-label, multicenter AUGMENT-101 study. The current labeling dataset included 104 adults and pediatric patients with relapsed or refractory KMT2A-translocated acute leukemia.

The population included:

• AML in 83%

• Acute lymphoblastic leukemia in 15%

• Mixed-phenotype acute leukemia in 2%

• A median of two prior treatment regimens

• Prior stem cell transplantation in 44%

The CR plus CRh rate was 21.2%, with a median CR plus CRh duration of 6.4 months. The median follow-up was 5.7 months. Twenty-four patients, or 23%, underwent hematopoietic stem cell transplantation after revumenib treatment.

These findings demonstrate antileukemic activity in a heavily pretreated population. They should be interpreted as response data, not as definitive evidence of durable disease control, superior survival, or improved transplantation outcomes.

NPM1-mutated AML

The later NPM1 indication was based on a separate single-arm AUGMENT-101 cohort. The current labeling dataset included 65 patients with relapsed or refractory NPM1-mutated AML.

The median age was 65 years, and the median number of prior regimens was two. Approximately 23% had undergone prior stem cell transplantation.

The CR plus CRh rate was 23.1%, with a median response duration of 4.5 months. The median follow-up was 3.8 months. Seven patients, or 11%, underwent transplantation after revumenib.

The peer-reviewed AUGMENT-101 report included 84 treated patients and a protocol-defined efficacy population of 64 adults. Seventy-five percent of the efficacy population had received prior venetoclax. The CR plus CRh rate was 23.4%, the overall response rate was 46.9%, and five of 30 responders proceeded to transplantation.

These data are clinically relevant because they include older, heavily pretreated patients. They do not establish revumenib as a validated transplant-bridging strategy or demonstrate improved post-transplant outcomes.

Revumenib dosing and administration

Revumenib should not be initiated until the white blood cell count is below 25 × 10⁹/L.

For patients weighing at least 40 kg:

• Without a strong CYP3A4 inhibitor: 270 mg orally twice daily

• With a strong CYP3A4 inhibitor: 160 mg orally twice daily

For patients weighing less than 40 kg:

• Without a strong CYP3A4 inhibitor: 160 mg/m² orally twice daily

• With a strong CYP3A4 inhibitor: 95 mg/m² orally twice daily

Revumenib can be administered in a fasted state or with a low-fat meal. Tablets should not be cut or chewed, although they may be crushed and dispersed in water according to the prescribing instructions.

Treatment should continue until disease progression or unacceptable toxicity. In patients without progression or unacceptable toxicity, labeling recommends treatment for at least 6 months to allow time for a clinical response.

Standard intrathecal chemotherapy prophylaxis is recommended in patients at risk for central nervous system relapse.

Evidence for Ziftomenib

Ziftomenib is an oral menin inhibitor administered at 600 mg once daily. It is approved for adults with relapsed or refractory AML harboring a susceptible NPM1 mutation when no satisfactory alternative treatment options exist.

Approval was based on KO-MEN-001, also called KOMET-001, an open-label, single-arm, multicenter study of 112 adults.

The population had:

• A median age of 69 years

• A median of two prior treatment lines

• Prior stem cell transplantation in 23%

• A median follow-up of 4.2 months

The CR plus CRh rate was 21.4%, with a median CR plus CRh duration of 5 months. Four patients, or 3.6%, underwent stem cell transplantation after ziftomenib treatment.

The results demonstrate clinically meaningful activity in heavily pretreated NPM1-mutated AML. The short follow-up and single-arm design do not establish durable survival benefit or superiority to another salvage regimen.

Ziftomenib is not approved for KMT2A-rearranged AML

Ziftomenib’s indication should not be extrapolated to KMT2A-rearranged disease.

Current prescribing information states that four fatal cases of differentiation syndrome occurred among 39 patients with KMT2A-rearranged AML who received ziftomenib in clinical trials. The label explicitly states that ziftomenib is not approved for KMT2A-rearranged AML.

This is an important example of why class-wide assumptions are unsafe. Revumenib and ziftomenib share a general target but have different approved populations, dosing, interaction profiles, and safety experience.

Ziftomenib dosing and administration

Ziftomenib should not be initiated until the white blood cell count is below 25 × 10⁹/L.

The recommended dose is 600 mg orally once daily until disease progression or unacceptable toxicity. In patients without confirmed progression or unacceptable toxicity, treatment for at least 6 months is recommended to allow time for a response.

Ziftomenib must be taken on an empty stomach, at least 1 hour before or 2 hours after a meal. A high-fat meal increases ziftomenib exposure approximately fourfold.

Capsules should be swallowed whole and should not be opened, broken, or chewed.

Cross-Trial Comparisons Are Not Reliable

The response rates for revumenib and ziftomenib appear numerically similar, but direct comparison is inappropriate.

The studies differed in:

• Age and pediatric enrollment

• Molecular populations

• Acute leukemia subtype

• Prior therapy

• Previous transplantation

• Follow-up duration

• Eligibility criteria

• Response definitions and analysis populations

• Permitted concomitant medications

The revumenib KMT2A cohort included AML, ALL, and mixed-phenotype acute leukemia in adults and children. The revumenib NPM1 cohort included adults and one pediatric patient. The ziftomenib pivotal population included only adults with NPM1-mutated AML.

Differences in follow-up are especially important. Median follow-up was 5.7 months for the revumenib KMT2A label population, 3.8 months for the revumenib NPM1 population, and 4.2 months for the ziftomenib population.

CR plus CRh and transfusion-independence conversion are clinically meaningful endpoints in relapsed acute leukemia. They do not by themselves establish durable remission, overall-survival benefit, or equivalence between agents.

Patient Selection

Patient selection begins with molecular confirmation.

AML evaluation should incorporate cytogenetic testing and molecular profiling at diagnosis. At relapse, repeat testing may be clinically appropriate because treatment pressure can alter clonal composition and because current therapeutic options depend on precise molecular eligibility.

Revumenib eligibility

Revumenib is appropriate only when one of its labeled molecular settings is present:

• Relapsed or refractory acute leukemia with a KMT2A translocation

• Relapsed or refractory AML with a susceptible NPM1 mutation and no satisfactory alternative treatment option

For the KMT2A indication, patient selection requires an FDA-authorized test. An FDA-approved companion diagnostic for the NPM1 indication is not currently available.

Ziftomenib eligibility

Ziftomenib is appropriate only for adults with:

• Relapsed or refractory AML

• A susceptible NPM1 mutation

• No satisfactory alternative treatment option

Neither agent should be used as generic salvage therapy for AML without molecular eligibility.

Broader clinical assessment

Before treatment, clinicians should review:

• White blood cell count

• Baseline QTc

• Potassium and magnesium

• Other relevant electrolyte abnormalities

• Blood counts and transfusion needs

• Liver and kidney function

• Active infection

• Concomitant medications

• Ability to adhere to oral therapy

• Reproductive status

• Transplant eligibility and goals of care

For patients who may be eligible for transplantation, early discussion with the transplant team is appropriate. The decision to proceed remains individualized and depends on response depth, measurable residual disease, prior transplantation, comorbidities, donor availability, disease risk, and patient preferences.

Differentiation Syndrome

Differentiation syndrome is the signature toxicity of menin inhibition and can be fatal.

Clinical manifestations may include:

• Fever

• Dyspnea or hypoxia

• Pulmonary infiltrates

• Pleural or pericardial effusions

• Rapid weight gain

• Peripheral edema

• Hypotension

• Acute kidney injury or renal dysfunction

• Rash

• Musculoskeletal or joint symptoms

These findings overlap with infection, pulmonary edema, transfusion reactions, leukemic progression, hemorrhage, and other drug toxicities. Treatment should begin when differentiation syndrome is clinically suspected rather than waiting for diagnostic certainty.

Revumenib management

When differentiation syndrome is suspected:

1. Initiate systemic corticosteroids immediately.

2. Begin hemodynamic monitoring and supportive care.

3. Continue corticosteroid treatment until symptom resolution and for at least 3 days.

4. Interrupt revumenib if severe symptoms persist for more than 48 hours after corticosteroid initiation.

5. Interrupt earlier for life-threatening symptoms, including pulmonary symptoms requiring ventilatory support.

6. Resume at the same dose when symptoms improve to grade 1 or lower.

Ziftomenib management

When differentiation syndrome is suspected:

1. Interrupt ziftomenib.

2. Initiate oral or intravenous corticosteroids.

3. Provide hemodynamic and laboratory monitoring and supportive care.

4. Continue corticosteroids for at least 3 days.

5. Taper corticosteroids over at least 3 days after adequate control.

6. Resume ziftomenib at the same dose when symptoms improve to grade 2 or lower.

Prompt management is required by labeling, but the available evidence should not be described as proving a quantified reduction in morbidity or mortality from a particular management protocol.

QTc Prolongation and Cardiac Monitoring

Both currently approved menin inhibitors can prolong the QTc interval, but their labeling differs.

Revumenib

Revumenib carries a boxed warning for QTc prolongation and Torsades de Pointes.

Before treatment:

• Correct hypokalemia and hypomagnesemia.

• Correct other clinically relevant electrolyte abnormalities.

• Do not initiate treatment when QTcF is greater than 450 msec.

Monitoring includes:

• ECG before initiation

• ECG at least weekly during the first 4 weeks

• ECG at least monthly thereafter

• More frequent monitoring in higher-risk patients

The label provides specific interruption, dose-reduction, and permanent-discontinuation instructions according to QTc severity and the presence of life-threatening arrhythmia.

Ziftomenib

Ziftomenib includes QTc prolongation under warnings and precautions but not in its boxed warning.

Before treatment:

• Correct hypokalemia and hypomagnesemia.

• Do not initiate treatment when QTcF is greater than 480 msec.

Monitoring includes:

• ECG before initiation

• ECG at least weekly during the first 4 weeks

• ECG at least monthly thereafter

• More frequent monitoring for congenital long QT syndrome, heart failure, electrolyte abnormalities, or concomitant QT-prolonging therapy

Ziftomenib should be interrupted when QTc exceeds 500 msec or increases by more than 60 msec from baseline.

The thresholds are agent-specific and should not be combined into a general class rule.

Other Adverse Events

Patients receiving menin inhibitors frequently have advanced leukemia, extensive prior treatment, baseline cytopenias, infection risk, transfusion requirements, and organ dysfunction. Adverse events must therefore be interpreted in clinical context.

Important events reported with revumenib include:

• Hemorrhage

• Febrile neutropenia

• Infections

• QTc prolongation

• Differentiation syndrome

• Nausea and diarrhea

• Musculoskeletal pain

• Edema

• Liver-enzyme abnormalities

• Creatinine elevation

• Potassium abnormalities

Important events reported with ziftomenib include:

• Infections

• Hemorrhage

• Febrile neutropenia

• Differentiation syndrome

• Diarrhea and nausea

• Fatigue

• Edema

• Musculoskeletal pain

• QTc prolongation

• Transaminase elevation

• Kidney laboratory abnormalities

• Potassium abnormalities

These toxicities should not be minimized by characterizing menin inhibitors as selectively preserving normal hematopoiesis. Conversely, events common in relapsed AML should not automatically be attributed solely to the study drug.

Drug-Interaction Considerations

Medication review is central to safe menin-inhibitor use because patients with AML commonly receive azole antifungals, antibacterial prophylaxis, antiemetics, anticonvulsants, QT-prolonging medications, and acid-suppressive therapy.

Revumenib interactions

Revumenib is primarily metabolized by CYP3A4.

• Reduce the revumenib dose when a strong CYP3A4 inhibitor is required.

• Avoid strong or moderate CYP3A4 inducers.

• Avoid QTc-prolonging medications when possible.

• If QTc-prolonging therapy cannot be avoided, intensify ECG monitoring.

Strong azole antifungals can substantially increase revumenib exposure. Dose selection should follow the prescribing information rather than applying a general empirical reduction.

Moderate CYP3A4 inhibitors such as fluconazole and isavuconazole did not produce clinically significant pharmacokinetic changes in the label’s cited interaction analyses, but the complete medication and risk context still requires review.

Ziftomenib interactions

Ziftomenib is primarily metabolized by CYP3A.

• Strong or moderate CYP3A4 inhibitors can increase exposure and require more frequent monitoring for adverse reactions.

• Strong or moderate CYP3A4 inducers should be avoided.

• Proton pump inhibitors should be avoided.

• H2-receptor antagonists and locally acting antacids should generally be avoided or separated from ziftomenib.

When an H2-receptor antagonist cannot be avoided, ziftomenib should be taken 2 hours before or 10 hours afterward.

When a locally acting antacid cannot be avoided, ziftomenib should be taken 2 hours before or 2 hours afterward.

Proton pump inhibitors reduced ziftomenib exposure substantially in pharmacokinetic studies. High-fat meals markedly increased exposure, supporting the strict empty-stomach requirement.

Pharmacist involvement

Clinical-pharmacy review is appropriate before treatment and at major transitions of care.

Medication reconciliation should include:

• Prescription medications

• Nonprescription acid suppressants

• Antiemetics

• QT-prolonging agents

• Antifungal prophylaxis

• Anticonvulsants

• Rifamycins

• Macrolides

• Herbal products and dietary supplements

Dose adjustments and medication substitutions should follow the individual product label and the patient’s clinical context.

Reproductive, Lactation, and Pediatric Considerations

Both approved menin inhibitors can cause fetal harm based on animal findings and mechanism of action. Pregnancy testing and contraception requirements differ by agent.

Revumenib

• Verify pregnancy status within 7 days before initiation.

• Females of reproductive potential should use effective contraception during treatment and for 4 months after the final dose.

• Males of reproductive potential should use effective contraception during treatment and for 4 months after the final dose.

• Breastfeeding is not recommended during treatment or for 1 week after the final dose.

• Animal data suggest possible fertility impairment, although the observed effects were reversible.

• Monitor bone growth and development in pediatric patients because irreversible growth-plate changes occurred in juvenile-animal studies.

Revumenib is approved in pediatric patients aged 1 year or older.

Ziftomenib

• Verify pregnancy status before initiation.

• Females of reproductive potential should use effective contraception during treatment and for 6 months after the final dose.

• Males with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the final dose.

• Breastfeeding is not recommended during treatment or for 2 weeks after the final dose.

• Animal studies suggest possible impairment of male and female fertility.

• Safety and effectiveness have not been established in pediatric patients.

These intervals should not be combined into a class-wide recommendation.

Renal and Hepatic Function

No revumenib dosage adjustment is specified for mild to moderate renal impairment or mild to moderate hepatic impairment. The pharmacokinetics of revumenib in severe renal impairment, end-stage kidney disease, or severe hepatic impairment are unknown.

No ziftomenib dosage adjustment is required for mild to moderate renal impairment or mild to moderate hepatic impairment. Severe renal and severe hepatic impairment have not been studied.

The absence of a recommended adjustment in studied populations should not be interpreted as evidence of safety in severe organ impairment. Clinical monitoring remains necessary because acute kidney injury, creatinine elevation, electrolyte disturbances, and liver-enzyme abnormalities may occur during treatment or differentiation syndrome.

Practical Monitoring Priorities

Issue	Why it matters	Practical approach
Molecular eligibility	Determines on-label use	Confirm KMT2A translocation or susceptible NPM1 mutation
Baseline WBC	Hyperleukocytosis may increase early complications	Reduce WBC to below 25 × 10⁹/L before initiation
Differentiation syndrome	Potentially fatal	Educate the care team and begin agent-specific management promptly
QTc and electrolytes	Ventricular arrhythmia risk	Obtain baseline and serial ECGs and correct potassium and magnesium
CYP3A interactions	Alters exposure and toxicity risk	Review azoles, anticonvulsants, rifamycins, macrolides, and supplements
Acid suppression	Important for ziftomenib absorption	Avoid PPIs and separate H2 antagonists or antacids when unavoidable
Blood counts and infection	Advanced AML and treatment increase complication risk	Monitor counts, fever, bleeding, and infection closely
Liver and kidney function	Laboratory abnormalities and differentiation syndrome may affect organs	Obtain baseline and serial laboratory testing
Reproductive safety	Both agents can cause fetal harm	Follow agent-specific testing, contraception, and lactation guidance
Transplant strategy	Response may create an opportunity	Coordinate early with the leukemia and transplant teams

Clinical Role in Relapsed or Refractory AML

Menin inhibitors should be regarded as molecularly selected treatment options rather than broad salvage therapy.

For a patient with relapsed or refractory KMT2A-translocated acute leukemia, revumenib may provide an opportunity for remission and possible transplantation.

For an adult with relapsed or refractory NPM1-mutated AML and no satisfactory alternative, revumenib or ziftomenib may be considered. Selection may be influenced by:

• Age

• Labeling

• Dosing schedule

• Ability to comply with fasting requirements

• Acid-suppressive therapy

• CYP3A interactions

• QTc risk

• Prior toxicity

• Access and insurance coverage

• Clinician and institutional experience

For pediatric patients with eligible NPM1-mutated AML, revumenib is currently the labeled option because ziftomenib is approved only for adults.

In potentially transplant-eligible responders, early transplant consultation is appropriate because median response durations in the pivotal datasets are measured in months. However, not every responder should undergo transplantation, and the optimal timing has not been established.

In patients who are not transplant candidates, clinically meaningful goals may include remission, transfusion independence, symptom improvement, or temporary disease control. Curative intent should not be implied when the overall treatment strategy is noncurative.

Combination Therapy and Earlier Treatment

Combination therapy is a major area of clinical investigation.

Menin inhibitors are being studied with:

• Azacitidine

• Venetoclax

• Intensive chemotherapy

• FLT3 inhibitors

• Other targeted agents

• Post-transplant approaches

A phase I study evaluated azacitidine, venetoclax, and revumenib in 43 adults aged 60 years or older with newly diagnosed NPM1-mutated or KMT2A-rearranged AML.

The reported overall response rate was 88.4%, and the composite complete-remission rate was 81.4%. Differentiation syndrome occurred in 19%, and QTcF prolongation was reported in 44%. All 37 patients evaluated for measurable residual disease by centralized flow cytometry had no detectable disease by that assay.

These findings are encouraging but remain preliminary. The study was a small, nonrandomized phase I trial without a comparator group. High response and measurable residual disease negativity rates do not establish superior overall survival, event-free survival, or safety compared with established frontline regimens.

The triplet should therefore remain investigational unless incorporated into approved labeling or authoritative guideline-supported practice.

Combination regimens may also increase:

• Cytopenia duration

• Infection risk

• Drug-interaction complexity

• QTc-management complexity

• Differentiation syndrome

• Treatment interruptions

Randomized studies and longer follow-up are needed before a menin-inhibitor combination can be presented as a new standard of care.

Measurable Residual Disease

NPM1 is an important molecular marker for measurable residual disease assessment. MRD can provide prognostic information and may help characterize response depth.

Menin-inhibitor trials have reported MRD negativity in selected responders, but several limitations remain:

• Assay methods differ.

• Not every patient is evaluable.

• Timing of assessment varies.

• MRD negativity is not equivalent to cure.

• MRD has not been validated as a surrogate for overall survival in this treatment context.

MRD-directed menin-inhibitor strategies would use molecular or flow-cytometric evidence of residual leukemia to guide treatment selection, timing, or duration. Whether such strategies reduce relapse or improve survival remains investigational.

Resistance and Disease Evolution

Resistance is an expected challenge with targeted therapy.

Acquired MEN1 mutations at the drug-menin interface have been documented clinically as a mechanism of resistance to revumenib. These mutations can reduce drug binding while maintaining the menin functions required for leukemic growth.

Other possible resistance mechanisms include:

• Clonal evolution

• Persistence of non-menin-dependent subclones

• Pathway bypass

• Changes in differentiation state

• Altered transcriptional dependencies

These mechanisms are not equally established. Acquired MEN1 interface mutations have direct clinical evidence, while several other mechanisms remain biologically plausible or under investigation.

Repeat marrow assessment and molecular profiling at progression may help distinguish persistent target dependence from clonal escape.

Switching from one menin inhibitor to another after resistance should be considered investigational unless supported by clinical-trial data or expert-directed compassionate-use circumstances. Clinicians should not assume that a leukemia remains sensitive to menin inhibition after progression on one agent.

Implications for Non-Hematology Specialists

Menin inhibitors will increasingly appear on hospital medication lists, transfer summaries, and consultation notes.

Cardiologists may be asked to evaluate QTc prolongation, electrolyte disturbances, or competing QT-prolonging medications.

Infectious disease clinicians and pharmacists may need to balance antifungal prophylaxis against CYP3A and QTc interactions.

Pulmonologists, intensivists, and hospitalists may evaluate dyspnea, hypoxia, infiltrates, effusions, or edema that could reflect infection, pulmonary edema, hemorrhage, leukemic progression, or differentiation syndrome.

Nephrologists may encounter acute kidney injury during differentiation syndrome, infection, volume disturbances, or nephrotoxic supportive therapy.

The clinically useful question is not merely whether the patient is receiving a targeted AML drug. It is whether a new presentation could represent differentiation syndrome, an avoidable interaction, QTc risk, or another complication requiring treatment interruption and urgent hematology input.

Limitations of the Evidence

The evidence supporting approved menin inhibitors is clinically meaningful but still maturing.

The major limitations include:

• Single-arm study designs

• No randomized active comparator

• Response-based primary endpoints

• Relatively short median follow-up

• Molecularly and clinically selected cohorts

• Limited post-transplant outcome data

• Uncertain optimal treatment duration

• Uncertain sequencing after venetoclax

• Limited evidence after prior menin-inhibitor exposure

• No established strategy for switching agents after resistance

• Investigational combination and maintenance approaches

The NPM1-mutated pivotal populations were not uniformly young or minimally pretreated. The revumenib and ziftomenib NPM1 cohorts included many older patients, and the published revumenib cohort included substantial prior venetoclax exposure.

Generalizability concerns should therefore focus on the single-arm design, protocol-defined eligibility, organ-function requirements, molecular selection, limited follow-up, and lack of randomized comparison rather than incorrectly characterizing the cohorts as predominantly young.

Response endpoints are important in relapsed AML, particularly when they relieve transfusion dependence or create a potential transplant opportunity. They do not automatically establish durable survival benefit.

Future Directions

The next phase of menin-inhibitor development will involve:

• Randomized combination trials

• Earlier-line therapy

• Resistance-guided sequencing

• MRD-informed strategies

• Post-transplant maintenance studies

• Pediatric development

• Next-generation inhibitors

• Better characterization of co-mutation effects

• Strategies to prevent or overcome acquired MEN1 resistance

Randomized trials are needed to determine whether adding menin inhibition to established therapy improves:

• Event-free survival

• Overall survival

• Remission durability

• Transplant eligibility

• Post-transplant relapse

• Patient-reported quality of life

Future work should also determine whether maintenance therapy after transplantation provides benefit, whether sequential menin inhibition can overcome selected resistance mechanisms, and how combination regimens affect differentiation syndrome, infection, cytopenias, and treatment-related mortality.

Conclusion

Menin inhibitors are an important advance in molecularly selected relapsed or refractory acute leukemia. They have converted KMT2A translocations and susceptible NPM1 mutations from primarily diagnostic or prognostic findings into actionable therapeutic targets.

Their approved roles remain agent-specific. Revumenib is approved for KMT2A-translocated relapsed or refractory acute leukemia and for selected NPM1-mutated relapsed or refractory AML in adults and pediatric patients aged 1 year or older. Ziftomenib is approved only for selected adults with NPM1-mutated relapsed or refractory AML.

The pivotal studies demonstrate remission activity in heavily pretreated patients, but they do not establish superiority over other salvage approaches, durable survival benefit, or improved post-transplant outcomes.

The practical message is disciplined rather than celebratory:

• Confirm the molecular target.

• Use the agent within its labeled context.

• Reduce leukocytosis before treatment.

• Recognize and treat differentiation syndrome promptly.

• Monitor QTc and electrolytes according to the individual label.

• Manage CYP3A and acid-suppression interactions carefully.

• Address reproductive and pediatric safety.

• Coordinate early with the transplant team when appropriate.

• Avoid presenting investigational combinations, maintenance, or sequencing strategies as established standards.

Menin inhibitors have changed the therapeutic options available to selected patients. The most important remaining questions concern sequencing, combination therapy, resistance, remission durability, and whether response improvements translate into longer survival.

References

1. Arellano, M. L., Thirman, M. J., DiPersio, J. F., et al. (2025). Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: The AUGMENT-101 study. Blood, 146(9), 1065-1077. https://doi.org/10.1182/blood.2025028357. PMID: 40332046.

2. Arber, D. A., Orazi, A., Hasserjian, R. P., et al. (2022). International Consensus Classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data. Blood, 140(11), 1200-1228. https://doi.org/10.1182/blood.2022015850. PMID: 35767897.

3. Candoni, A., et al. (2024). A 2024 update on menin inhibitors: A new class of targeted agents against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia. Hematology Reports, 16(2), 262-280. https://doi.org/10.3390/hematolrep16020030. PMID: 38651453.

4. DailyMed. (2026). Revuforj: Revumenib tablets, prescribing information. Updated February 4, 2026. Retrieved July 29, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6eb3cdbc-0e74-477d-82d6-3bb172d3f63f

5. DailyMed. (2025). Komzifti: Ziftomenib capsules, prescribing information. Updated December 9, 2025. Retrieved July 29, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b650f696-3391-4274-8b55-a5f5e9d04769

6. Döhner, H., Wei, A. H., Appelbaum, F. R., et al. (2022). Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the European LeukemiaNet. Blood, 140(12), 1345-1377. https://doi.org/10.1182/blood.2022016867. PMID: 35797463.

7. Issa, G. C., Aldoss, I., Thirman, M. J., et al. (2025). Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia: AUGMENT-101. Journal of Clinical Oncology, 43(1), 75-84. https://doi.org/10.1200/JCO.24.00826. PMID: 39121437.

8. Issa, G. C., Aldoss, I., DiPersio, J., et al. (2023). The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukemia. Nature, 615(7954), 920-924. https://doi.org/10.1038/s41586-023-05812-3. PMID: 36922593.

9. Khoury, J. D., Solary, E., Abla, O., et al. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and histiocytic/dendritic neoplasms. Leukemia, 36(7), 1703-1719. https://doi.org/10.1038/s41375-022-01613-1. PMID: 35732831.

10. Perner, F., Stein, E. M., Wenge, D. V., et al. (2023). MEN1 mutations mediate clinical resistance to menin inhibition. Nature, 615(7954), 913-919. https://doi.org/10.1038/s41586-023-05755-9. PMID: 36922589.

11. U.S. Food and Drug Administration. (2024, November 15). FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation

12. U.S. Food and Drug Administration. (2025, October 24). FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation

13. U.S. Food and Drug Administration. (2025, November 13). FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with an NPM1 mutation. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation

14. Wang, E. S., Issa, G. C., Erba, H. P., et al. (2024). Ziftomenib in relapsed or refractory acute myeloid leukaemia: A multicentre, open-label, multi-cohort, phase 1 trial. The Lancet Oncology, 25(10), 1310-1324. https://doi.org/10.1016/S1470-2045(24)00386-3. PMID: 39362248.

15. Wang, E. S., Montesinos, P., Foran, J., et al. (2025). Ziftomenib in relapsed or refractory NPM1-mutated AML. Journal of Clinical Oncology, 43(31), 3381-3390. https://doi.org/10.1200/JCO-25-01694. PMID: 40997296.

16. Zeidner, J. F., Lin, T. L., Welkie, R. L., et al. (2025). Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML. Journal of Clinical Oncology, 43(23), 2606-2615. https://doi.org/10.1200/JCO-25-00914. PMID: 40504618.